Psychedelic Alpha’s Josh Hardman speaks with Compass Pathways CEO, Kabir Nath, about a range of topics: from the company’s recently-announced agreements that could shed light on what the roll-out of COMP360 psilocybin therapy might look like, through to the motivation behind its distinctive ‘psychological support’ model and Nath’s thoughts on a competitor’s fast follower strategy.
